Peptide Report
LL37 Peptide Report
Catalog report for LL37, generated from Peptide Stacks product data and linked to the matching PeptideReports protocol page when available.
Current Price$50.00 – $119.99 CAD
Common Uses
People commonly discuss LL-37 for immune-support and antimicrobial peptide research, with interest often centered on resilience, skin, and recovery contexts.
How It Works
LL-37 is a human cathelicidin antimicrobial peptide. It can interact with microbial membranes and also modulate immune signaling, chemotaxis, inflammation, and wound-healing pathways in host-defense research.
Storage
Powder form: In lyophilized powder form, LL37 is generally kept sealed, dry, protected from direct light, and refrigerated unless the product label or certificate of analysis gives different handling instructions. Avoid leaving vials in hot rooms, vehicles, direct sunlight, or other temperature swings, because moisture, heat, and light are the main storage conditions people try to control before reconstitution.
Reconstituted: After reconstitution, LL37 should generally be treated as more sensitive: keep it refrigerated, minimize unnecessary handling, avoid shaking, and use clean handling practices each time the vial is accessed. Follow the product label, protocol page, and any pharmacy or lab guidance for beyond-use timing; if the solution changes color, becomes cloudy, develops particles, or the vial integrity is questionable, it should not be used.
Protocol
The full LL37 protocol is included below. The standalone protocol page remains available if you want to open it separately.
Open Standalone Protocol
Scope
Preparation examples, syringe conversion, community-reported patterns and important limitations.
Available strengths: 5 MG and 10 MG
Preparation Examples
These are calculation examples only. The concentration assumptions below are explicit so syringe units are never separated from vial strength and diluent volume.
| Setup |
Diluent |
Concentration |
Unit conversion |
| 5 MG vial – 2 mL example |
Add 2 mL bacteriostatic water |
2.5 mg/mL |
Each U-100 unit = 25 mcg |
| 10 MG vial – 2 mL example |
Add 2 mL bacteriostatic water |
5 mg/mL |
Each U-100 unit = 50 mcg |
Syringe Conversion
| Reported amount |
5 MG setup |
10 MG setup |
| 50 mcg |
2 units |
1 units |
| 100 mcg |
4 units |
2 units |
| 250 mcg |
10 units |
5 units |
| 500 mcg |
20 units |
10 units |
Always recalculate from the actual vial strength and diluent volume. A U-100 unit is 0.01 mL; it is not a dose by itself.
Community-Reported Patterns
| Recurring report |
Frequency seen |
Context in reports |
| 50-100 mcg |
Once daily |
Lower-start reports |
| 100-250 mcg |
Once daily |
Most recurring range |
| 500 mcg |
Daily in some reports |
Higher experimental use |
Observations
- Community discussions most often centered on innate-immunity, biofilm and persistent-infection research.
- The amount, frequency, route and cycle length varied substantially between reports.
- Reported outcomes were commonly confounded by diet, training, other products or existing treatment.
Caveats
- Immune activation, inflammatory reactions and worsening symptoms are possible; infection concerns require qualified medical evaluation.
- Community reports are uncontrolled anecdotes and do not establish an appropriate dose, safety, product identity, purity or efficacy.